Compliance Policy Guide: RFID Studies and Pilot Programs for Drugs
FDA is extending the expiration date of the compliance policy guide (CPG) Sec. 400.210 entitled ‘‘Radiofrequency Identification (RFID) Feasibility Studies and Pilot Programs for Drugs’’ to December 31, 2012.
FDA has identified RFID as a promising technology to be used in the various efforts to combat counterfeit drugs. The CPG describes how the Agency intends to exercise its enforcement discretion regarding certain regulatory requirements that might otherwise be applicable to studies involving RFID technology for drugs. The goal of the CPG is to facilitate performance of RFID studies and to allow industry to gain experience with the use of RFID technology and its effect on the longterm safety and integrity of the U.S. drug supply.
Please find additional information at: http://edocket.access.gpo.gov/2010/pdf/2010-32274.pdf
Source: FDA Press Release
Related GMP News
31.07.2024Report on Trends in the Falsification of Medicines
11.06.2024Serialization - Version 21 of the Q&As on Safety Features
17.01.2024Ozempic Falsification also in the US
20.12.2023US Track & Trace Guidance on Verification Systems
07.12.2023Falsification of Ozempic Confirmed
18.10.2023Ozempic Falsifications: BfArM starts Investigation